Pharma & Biotech Global Week in Review 15 December 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

EPO Enlarged Board of Appeal decides Broccoli (G2/07) and Tomatoes (G1/08) – essentially biological breeding processes not patentable (IPKat) (IP Watch) (K’s Law)

US IRS issues notice to implement annual fee on brand drugs (FDA Law Blog)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

Coming soon: International Classification of traditional medicine by WHO (Spicy IP)

Teva Pharma uses online game to promote generic substitution (Patent Baristas)

Australia: APO: Success of phase 3 trials ‘obvious’ in view of phase 1 and 2: Genentec, Inc (Patentology)

Brazil: Government support to impel Brazil generic market (GenericsWeb)

EU: EPO Enlarged Board of Appeal decides Broccoli (G2/07) and Tomatoes (G1/08) – essentially biological breeding processes not patentable (IPKat) (IP Watch) (K’s Law)

India: Comptroller of Auditor General demands improvement from National Biodiversity Authority (Spicy IP)

US: Adjusting the inequitable conduct doctrine: Federal Circuit hears oral arguments: Therasense, Inc. v. Becton, Dickinson & Co (Intellectual Property Law Blog)

US: Regents of the University of California pursue new patent re-examination in District Court (Patents Post Grant Blog)

US: Microsoft v i4i, the burden of proof and the pharma sector (PatLit)

US: IRS issues notice to implement annual fee on brand drugs (FDA Law Blog)

US: Bright ‘orphan’ ideas blossom (FDA Law Blog)

US: Amicus briefs in AMP v USPTO (Patent Docs) (Patent Docs) (Patent Docs)

US: University of California files for reversal of BPAI decision concerning patent covering ‘Dietary composition for enhancing metabolism and alleviating oxidative stress’ (Patent Docs)

US: Cellectis files patent infringement suit against Precision Biosciences over directed nuclease editor technology (Patent Docs)

US: Monsanto files patent infringement suit against Zeferino Sauceda based on use of saved Roundup Ready or Bollgard seed (Patent Docs)

US: Bayer CropScience files patent infringement complaint against Dow Agrosciences over transgenic plants and/or 2,4-D herbicide resistant seeds (Patent Docs)

Products

Boniva (Ibandronate) – US: Hoffmann-La Roche files patent infringement complaint against Watson, Cobalt in response to Para IV certification (Patent Docs)

Boniva (Ibandronate) – US: Hoffmann-La Roche files patent infringement complaint against Apotex in response to Para IV certification (Patent Docs)

Cipro (Ciprofloxacin) – US: Drug purchasers petition Supreme Court to consider CIPRO patent settlement case (FDA Law Blog)

Concerta (Methylphenidate) – US: Alza, Ortho-McNeil-Janssen files patent infringement complaint following Para IV certification filing (Patent Docs)

Cozaar / Hyzaar (Losartan) – US: Apotex cert petition on 180-day exclusivity forfeiture decision is DOA, says Teva in opposition brief (FDA Law Blog)

Exalgo (Hydromorphone) – US: Watson confirms Exalgo patent challenge (SmartBrief)

Fabrazyme (Agalsidase beta) – US: Health & Human Services denies request to exercise Bayh-Dole ‘march-in’ rights for Fabrazyme (Patent Docs)

Herceptin (Trastuzumab) – US: NIH funded research involving Trastuzumab (marketed by Roche under the trade name Herceptin) (KEI)

Intuniv (Guanfacine) – US: Shire, Supernus file suit to block Impax, others to block generic Intuniv (Patent Docs)

Lotrel (Amlodipine, Benazepril) – US: Novartis files patent infringement complaint against Aurobindo in response to Para IV certification (Patent Docs)

Lovenox (Enoxaparin) – US: Momenta, Sandoz file patent infringement suit against Teva over expected manufacture and sale of generic Lovenox (Patent Docs)

Propecia (Finasteride) – US: Merck files patent infringement suits against Hetero following Para IV certification filing (Patent Docs)

Seroquel XR (Quetiapine) – US: AstraZeneca files patent infringement complaint against Mylan following Para IV certification filing (Patent Docs)

Simcor (Niacin, Simvastatin) – US: Abbott files patent infringement suit against Impax in response to Para IV challenge (Patent Docs)

Solodyn (Minocycline) – US: Medicis files patent infringement complaint against Aurobindo in response to Para IV certification (Patent Docs)

Taxotere (Docetaxel) – France: Tribunale de Grande Instance: Imminent infringement not sufficiently established, Aventis request for injunctions against Teva, Hospira and Intas denied (Kluwer Patent Blog)

Viread (Tenofovir) – India: Questionable letter from US Commerce Secretary to Indian counterpart regarding Gilead’s pending patent appeal (Spicy IP)

Welchol (Colesevelam) – US: Daiichi Sankyo, Genzyme file patent infringement complaint against Impax, Glenmark following Para IV challenge (Patent Docs)

Xyrem (Sodium oxybate) – US: Jazz file patent infringement complaint against Roxane following Para IV certification filing (Patent Docs)

Zemplar (Paricalcitol) US: Abbot, WARF file patent infringement complaint against Roxane following Para IV certification (Patent Docs)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: